Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Strayer

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|December 3, 2011
Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodiesDavid R Strayer, William A Carter
Plos One|October 29, 2020
Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue SyndromeDavid R Strayer, Diane Young, William M Mitchell
Infectious Disorders Drug Targets|July 15, 2014
Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humansDavid R Strayer, Robert Dickey, William A Carter
In Vivo (Athens, Greece)|June 21, 2002
Physical performance and prediction of 2-5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndromeChristopher R Snell, J Mark Vanness, David R Strayer, et al.
In Vivo (Athens, Greece)|March 31, 2005
Exercise capacity and immune function in male and female patients with chronic fatigue syndrome (CFS)Christopher R Snell, J Mark Vanness, David R Strayer, et al.
Medicine and Science in Sports and Exercise|June 5, 2003
Subclassifying chronic fatigue syndrome through exercise testingJ Mark Vanness, Christopher R Snell, David R Strayer, et al.
The American Journal of Pathology|February 4, 2014
Discordant biological and toxicological species responses to TLR3 activationWilliam M Mitchell, Christopher F Nicodemus, William A Carter, et al.
Vaccine|August 17, 2014
Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humansEdgar Turner Overton, Paul A Goepfert, Pamela Cunningham, et al.
Expert Review of Anti-Infective Therapy|December 20, 2013
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatmentQinfang Liu, Jingjiao Ma, David R Strayer, et al.
Antiviral Research|August 12, 2014
Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administered to the buccal mucosaDavid R Strayer, William A Carter, Bruce C Stouch, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|December 3, 2011
Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodiesDavid R Strayer, William A Carter
Plos One|October 29, 2020
Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue SyndromeDavid R Strayer, Diane Young, William M Mitchell
Infectious Disorders Drug Targets|July 15, 2014
Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humansDavid R Strayer, Robert Dickey, William A Carter
In Vivo (Athens, Greece)|June 21, 2002
Physical performance and prediction of 2-5A synthetase/RNase L antiviral pathway activity in patients with chronic fatigue syndromeChristopher R Snell, J Mark Vanness, David R Strayer, et al.
In Vivo (Athens, Greece)|March 31, 2005
Exercise capacity and immune function in male and female patients with chronic fatigue syndrome (CFS)Christopher R Snell, J Mark Vanness, David R Strayer, et al.
Medicine and Science in Sports and Exercise|June 5, 2003
Subclassifying chronic fatigue syndrome through exercise testingJ Mark Vanness, Christopher R Snell, David R Strayer, et al.
The American Journal of Pathology|February 4, 2014
Discordant biological and toxicological species responses to TLR3 activationWilliam M Mitchell, Christopher F Nicodemus, William A Carter, et al.
Vaccine|August 17, 2014
Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humansEdgar Turner Overton, Paul A Goepfert, Pamela Cunningham, et al.
Expert Review of Anti-Infective Therapy|December 20, 2013
Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatmentQinfang Liu, Jingjiao Ma, David R Strayer, et al.
Antiviral Research|August 12, 2014
Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administered to the buccal mucosaDavid R Strayer, William A Carter, Bruce C Stouch, et al.
Pageof 2